A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

Abbreviations: AION, anterior ischemic optic neuropathy; BRAO, branch retinal artery occlusion; CWS, cotton-wool spots; ESR, erythrocyte sedimentation rate; GCA ...

Get Instant Summarized Text (Gist) Once-weekly semaglutide use in individuals with type 2 diabetes more than doubles the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

A RETROSPECTIVE case series has identified ophthalmic complications in patients using the antidiabetic drugs semaglutide and ...

the ophthalmologist then sees a diffuse swelling of the optic nerve (anterior ischemic optic neuropathy, AION) or posterior ischemic optic neuropathy (PION). If not treated, AION and PION result ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

Scleritis is the most common ocular manifestation of relapsing polychondritis; in one study, this sign was present in 51 out of 117 patients, and was the presenting feature in 6 patients.

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy in those with type 2 diabetes.

Findings seen for patients with type 2 diabetes during a 5-year period. (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...